The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)

Autor: Sasaki, K, Ribera, JM, Figueroa, M, Ravandi, F, Short, NJ, Garcia-Manero, G, Daver, NG, Kadia, TM, Konopleva, MY, Jain, N, Issa, GC, Estrov, ZE, Garris, R, Khouri, R, Nasnas, P, DiNardo, CD, Naqvi, K, Kornblau, SM, Montalban-Bravo, G, Pemmaraju, N, Cortes, JE, O'Brien, SM, Chandra, J, Kantarjian, HM, Jabbour, E

Publikováno v: Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::0fac2aac8bb0efb1b37881720e4a7a3e
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2982

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.

Autor: Goldfinger M; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Mantzaris I; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Shastri A; MONTEFIORE MEDICAL CENTER, Bronx, New York, United States., Saunthararajah Y; Cleveland Clinic, Cleveland, Ohio, United States., Gritsman K; Albert Einstein College of Medicine, Bronx, New York, United States., Sica A; Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States., Kornblum N; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States., Shah N; Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States., Levitz D; Montefiore Medical Center, New York City, New York, United States., Rockwell B; Albert Einstein College of Medicine - Montefiore Medical Center, Bronx, New York, United States., Shapiro LC; Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States., Gupta R; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Pradhan K; Albert Einstein College of Medicine, Bronx, New York, United States., Xue X; Albert Einstein College of Medicine, Bronx, United States., Munoz A; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Dhawan A; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Fehn K; Montefiore Medical Center, Bronx, New York, United States., Comas M; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States., Verceles JA; Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, Bronx, New York, United States., Jonas BA; University of California Davis, Sacramento, California, United States., Kambhampati S; Sarah Cannon Research Institute at Research Medical Ctr, Kansas City, Missouri, United States., Shi Y; Montefiore Medical Center, Bronx, New York, United States., Braunschweig I; Rutgers Cancer Institute, New Brunswick, New Jersey, United States., Cooper DL; Montefiore Medical Center, Bronx, New York, United States., Konopleva MY; Albert Einstein College of Medicine, New York, New York, United States., Feldman EJ; Montefiore Medical Center, New York City, New York, United States., Verma A; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States.

Publikováno v: Blood [Blood] 2024 Sep 24. Date of Electronic Publication: 2024 Sep 24.

Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.

Autor: Konopleva MY; University of Texas, MD Anderson Cancer Center, Houston, TX. Electronic address: mkonople@mdanderson.org., Dail M; Genentech, Inc., South San Francisco, CA., Daver NG; University of Texas, MD Anderson Cancer Center, Houston, TX., Garcia JS; Dana-Farber Cancer Institute, Boston, MA., Jonas BA; University of California Davis Comprehensive Cancer Center, Sacramento, CA., Yee KWL; Princess Margaret Cancer Centre, Toronto, ON, Canada., Kelly KR; University of Southern California, Los Angeles, CA., Vey N; Hematologie Clinique, Institut Paoli Calmettes, Marseille, France., Assouline S; Jewish General Hospital, Montreal, QC, Canada., Roboz GJ; Weill-Cornell Medical College, New York Presbyterian, New York, NY., Paolini S; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Pollyea DA; University of Colorado, Division of Hematology, Aurora, CO., Tafuri A; Department of Clinical and Molecular Medicine, University Hospital Sant'Andrea-Sapienza, Rome, Italy., Brandwein JM; Division of Hematology, University of Alberta, Edmonton, AB, Canada., Pigneux A; Bordeaux Haut-Leveque University Hospital, Pessac, France., Powell BL; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC., Fenaux P; Hôpital Saint-Louis, Université Paris Diderot, Paris, France., Olin RL; University of California San Francisco, San Francisco, CA., Visani G; Hematology, Ospedale San Salvatore, Pesaro, Italy., Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Onishi M; Genentech, Inc., South San Francisco, CA., Wang J; Genentech, Inc., South San Francisco, CA., Huang W; Genentech, Inc., South San Francisco, CA., Dunshee DR; Genentech, Inc., South San Francisco, CA., Hamidi H; Genentech, Inc., South San Francisco, CA., Ott MG; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Hong WJ; Prelude Therapeutics, Wilmington, DE., Andreeff M; University of Texas, MD Anderson Cancer Center, Houston, TX.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Jun; Vol. 24 (6), pp. 364-374. Date of Electronic Publication: 2024 Jan 18.

Correction: Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.

Autor: Tian Z; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ztian1@mdanderson.org., Shi C; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang G; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Allen JK; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shi Q; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Al-Shami A; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Olson JW; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Smith MG; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang Q; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kaur J; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., You J; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lofton TE; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gonzalez MA; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang Q; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zha D; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tasian SK; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Department of Pediatrics and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Jain N; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Heffernan T; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org.; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. TPHeffernan@mdanderson.org., Molldrem JJ; ORBIT Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jmolldre@mdanderson.org.; Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jmolldre@mdanderson.org.

Publikováno v: Leukemia [Leukemia] 2024 Jan; Vol. 38 (1), pp. 226.